Fulcrum Therapeutics downgraded by RBC Capital Mkts with a new price target

9/12/24 3:56:30 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

RBC Capital Mkts downgraded Fulcrum Therapeutics from Outperform to Sector Perform and set a new price target of $4.00 from $15.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$FULC

Date	Price Target	Rating	Analyst
5/23/2025	$12.00	Market Perform → Outperform	Leerink Partners
5/15/2025	$10.00	Neutral → Overweight	Cantor Fitzgerald
9/13/2024	$17.00 → $4.00	Buy → Neutral	H.C. Wainwright
9/12/2024	$15.00 → $4.00	Outperform → Sector Perform	RBC Capital Mkts
9/12/2024	$4.00	Outperform → Market Perform	Leerink Partners
9/12/2024	$10.00 → $2.00	Neutral → Underperform	BofA Securities
9/12/2024		Buy → Hold	Stifel
9/12/2024		Overweight → Neutral	Cantor Fitzgerald